Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation

被引:153
作者
Cope, AV
Sabin, C
Burroughs, A
Rolles, K
Griffiths, PD
Emery, VC
机构
[1] ROYAL FREE HOSP, SCH MED, DIV PATHOL & COMMUNICABLE DIS, DEPT VIROL, LONDON NW3 2PF, ENGLAND
[2] ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE, LONDON NW3 2PF, ENGLAND
[3] ROYAL FREE HOSP, SCH MED, DEPT POPULAT SCI, LONDON NW3 2PF, ENGLAND
[4] ROYAL FREE HOSP, SCH MED, LIVER TRANSPLANT UNIT, LONDON NW3 2PF, ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1086/514145
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Longitudinal analysis of 162 liver transplant recipients identified 51 patients who were viremic. Virus load was determined in 47 of these patients using quantitative-competitive polymerase chain reaction, Peak: virus load was significantly higher in 20 symptomatic patients than 27 asymptomatic patients (P < .0001), Elevated virus load, donor seropositivity, and total methylprednisolone dosage were risk factors for human cytomegalovirus (HCMV) disease (odds ratio [OR], 2.22/0.25 log(10) increase in virus load, P = .001; OR, 4.11, P = .05; OR, 130/1-g increment in methylprednisolone, P = .01), Methylprednisolone and virus load were independent risk factors in a multivariate analysis (OR, 2.70/1-g increase, P = .003; OR, 1.61/0.25 log(10) increase, P = .03, respectively). Virus loads of 10(4.75)-10(5.25) genomes/mL of blood were associated with an increased disease probability; the latter was shifted to lower virus loads with increasing quantities of methylprednisolone. These data illustrate the central role of virus load in HCMV pathogenesis.
引用
收藏
页码:1484 / 1490
页数:7
相关论文
共 34 条
  • [21] HIGH-LEVELS OF CIRCULATING CYTOMEGALOVIRUS DNA REFLECT VISCERAL ORGAN DISEASE IN VIREMIC IMMUNOSUPPRESSED PATIENTS OTHER THAN MARROW RECIPIENTS
    SALTZMAN, RL
    QUIRK, MR
    JORDAN, MC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) : 1832 - 1838
  • [22] COMPARISON OF POLYMERASE CHAIN-REACTION FROM PLASMA AND BUFFY COAT WITH ANTIGEN-DETECTION AND OCCURRENCE OF IMMUNOGLOBULIN-M FOR THE DEMONSTRATION OF CYTOMEGALOVIRUS-INFECTION AFTER LIVER-TRANSPLANTATION
    SCHMIDT, CA
    OETTLE, H
    PENG, RQ
    NEUHAUS, P
    BLUMHARDT, G
    LOHMANN, R
    WILBORN, F
    OSTHOFF, K
    OERTEL, J
    TIMM, H
    SIEGERT, W
    [J]. TRANSPLANTATION, 1995, 59 (08) : 1133 - 1138
  • [23] DEMONSTRATION OF CYTOMEGALOVIRUS BY POLYMERASE CHAIN-REACTION AFTER LIVER-TRANSPLANTATION
    SCHMIDT, CA
    OETTLE, H
    NEUHAUS, P
    WIENS, M
    TIMM, H
    WILBORN, F
    SIEGERT, W
    [J]. TRANSPLANTATION, 1993, 56 (04) : 872 - 874
  • [24] A RANDOMIZED, CONTROLLED TRIAL OF PROPHYLACTIC GANCICLOVIR FOR CYTOMEGALOVIRUS PULMONARY INFECTION IN RECIPIENTS OF ALLOGENEIC BONE-MARROW TRANSPLANTS
    SCHMIDT, GM
    HORAK, DA
    NILAND, JC
    DUNCAN, SR
    FORMAN, SJ
    ZAIA, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (15) : 1005 - 1011
  • [25] HIGH-DOSE ACYCLOVIR COMPARED WITH SHORT-COURSE PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED TRIAL
    SINGH, N
    YU, VL
    MIELES, L
    WAGENER, MM
    MINER, RC
    GAYOWSKI, T
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 120 (05) : 375 - 381
  • [26] SNYDMAN DR, 1994, TRANSPLANT P, V26, P20
  • [27] SRATTA RJ, 1992, ARCH SURG-CHICAGO, V127, P55
  • [28] COMPARATIVE SERIAL VIROLOGIC AND SEROLOGIC STUDIES OF SYMPTOMATIC AND SUBCLINICAL CONGENITALLY AND NATURALLY ACQUIRED CYTOMEGALOVIRUS INFECTIONS
    STAGNO, S
    REYNOLDS, DW
    TSIANTOS, A
    FUCCILLO, DA
    LONG, W
    ALFORD, CA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (05) : 568 - 577
  • [29] STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443
  • [30] DONATED ORGAN AS A SOURCE OF CYTOMEGALOVIRUS IN ORTHOTOPIC LIVER-TRANSPLANTATION
    SUTHERLAND, S
    BRACKEN, P
    WREGHITT, TG
    OGRADY, J
    CALNE, RY
    WILLIAMS, R
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1992, 37 (03) : 170 - 173